Advirna

03/06/2024

Advirna will present it’s siRNA drug discovery platform at ATGC24 conference.

11/17/2023

Research Highlights: The phase 2 study found that a single injection of the experimental medication zilebesiran safely and effectively lowered blood pressure in adults with mild-to-moderate hypertension for up to six months. Based on these results,...

10/25/2023

Advirna is presenting at 2023 OTS meeting in Barcelona

03/20/2023

Advirna will be presenting a poster at the Nucleic Acids Therapies conference at Cold Spring Harbor Laboratory (March 22-25).

09/02/2021

Advirna provides services in designing chemically stabilized siRNA conjugates for theraputic development and in vivo target validation.

Oligonucleotide therapies possess enormous potential as healing, life-changing, and cancer-curing drugs. However, there are many barriers to utilizing oligonucleotides to treat disease. Discovering or creating effective delivery methods for each target cell or tissue type solves many of these. There...

03/28/2021

Indeed... Just another fact which is not discuses broadly...

The first confirmed COVID-19 case in Africa was on February 14, 2020 in Egypt. The first in sub-Saharan Africa appeared in Nigeria soon after.

08/25/2020

We published a paper in Molecular Therapy Nucleic Acids demonstrating a potential use of self-deliverable siRNA conjugates (sdRNAs) to prevent ocular scarring

Ocular scarring after surgery, trauma, or infection leads to vision loss. The transparent cornea is an excellent model system to test anti-scarring th…

08/11/2020

Advrina is looking for an oligonucleotide chemist (MS or PhD) to set-up and run a small-to-mid scale syhthesis of modified siRNAs. Work autorization is required. Position is available immediately.

06/17/2020

Advirna is moving to a new location to a bigger lab to expand its operations. We will be back operating in a few days.
Thanks to MBI!
https://www.massbiomed.org

06/09/2020

Advirna has designed and validated self-deliverable siRNA conjugates targeting SARS-CoV-2 genome, human ACE2 and TMPRSS2. These compounds may be valuable tools in research associated with virus biology and therapeutic developemnt.